Search Results - asaf+alimardanov

6 Results

Sort By:

High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors

Summary: The NCI seeks licensing and/or co-development research collaborations for CD276-targeting camel nanobodies. Description of Technology: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li

Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies

Abstract: Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors. Researchers in the National...

Published: 5/14/2025 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Nan Li, Dan Li

Keywords(s): CANCER, chimeric antigen receptor (CAR), GPC2, GPC3, HO, MESOTHELIN, solid tumor, tumor antigen

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Cross Species Single Domain Antibodies Targeting PD-L1 for Treating Solid Tumors

Description of Technology: Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape. PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Mitchell Ho, Glenn Merlino, Dan Li, Hejiao English, Chi-Ping Day

Keywords(s): adoptive cell therapy, Chimeric Antigen Receptor T Cells, HO, ICI, Immune Checkpoint Inhibitor, Immunotherapy, NANOBODY, PD-L1, phage display, Programed Death-Ligand, Single Domain Antibody

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Novel ACRV1/ALK2 Inhibitors and Methods for Inhibiting BMP Signaling for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

This technology includes the identification and use of novel ACRV1/ALK2 inhibitors for the treatment of fibrodysplasia ossificans progressiva (FOP), an autosomal-dominant rare disease that affects one person in every 1-2 million. FOP is characterized by malformation of the great (big) toes during embryonic development and by progressive heterotopic...

Published: 8/13/2025 | Updated: 12/6/2022 | Inventor(s): Jiankang Jiang, Khalida Shamim, Philip Sanderson, Wei Zheng, Xiuli Huang, Gregory Tawa, Asaf Alimardanov, Arthur Lee, Junfeng Huang, Wenwei Huang

Keywords(s): ALK2, BMP, INHIBITING, Inhibitors, Methods, Novel, SIGNALING, VGXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Endocrinology, Application > Therapeutics, Application > Research Materials

Process for Practical, Scalable, Commercially-viable Method for the Synthesis of Enantio-enriched Aminoalcohols, Including the Novel Antifungal VT-1129 Used to Treat Cryptococcal Meningitis

This technology relates to the discovery and development of a practical, scalable, and commercially viable method for the synthesis of the novel antifungal VT-1129. Cryptococcal meningitis (CM) is a fungal infection that is particularly prevalent in immune-compromised patients and can be treated by VT-1129. CM has a current estimated patient population...

Published: 8/13/2025 | Updated: 12/6/2022 | Inventor(s): Mark Behnke, Scott David, Douglas Fry, William Hoekstra, Christopher Yates, Asaf Alimardanov

Keywords(s): Acid, Alcohol, Aminoalcohols, Benzenesulfonic, BSA., Co-crystal, Containing, Derivatives, Enantioenriched, Fragment, Including, Listed LPM Nguyen-Antczak as of 4/15/2015, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PROCESS, Synthesis, Tertiary, THOSE, VEXXXX, VT-1129, WMXXXX

Category(s): Application > Consumer Products, TherapeuticArea > Neurology

Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration

This technology includes the use of a novel formulation for an engineered version of Fibroblast Growth Factor 1 (FGF1), TTHX1114, that can be used to accelerate regeneration of the corneal endothelium after surgical lesions. FGFs are well-established regulators of migration and proliferation of corneal endothelial cells (CECs).

Published: 10/28/2024 | Updated: 12/6/2022 | Inventor(s): Vinay Vyas, Hui Fang Dong, Asaf Alimardanov, Gautam ("George") Mitra, Trevor Broadt, David Eveleth

Keywords(s): FGF-1, FORMULATION, Modified, PRESERVATION, STABLE, TTHX1114, VPXXXX, WIXXXX, WKXXXX, XEXXXX

Category(s): TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology, TherapeuticArea > Ophthalmology, Application > Therapeutics, TherapeuticArea > Dental, TherapeuticArea > Endocrinology, Application > Research Materials, TherapeuticArea > Cardiology